We also discovered the metastatic site-specific impact of driver oncogenes, such as BRAF and KRAS mutations, pointing out that the impact of driver alterations on survival outcomes can vary depending on the site of metastasis of CRC. This evidence concerns the gene KRAS and colorectal carcinoma.